Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 23;12:949511. doi: 10.3389/fonc.2022.949511

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ding, Yang, Yang, Sun, Chen, Li, Lowe, Guo, Tian, Liu and Zhao

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The relationship between sarcopenia and prognosis. (A) 2-year OS of patients in the pre-treatment sarcopenic group versus the non-sarcopenic group. (B) 2-year OS of patients in the post-treatment sarcopenic group versus the non-sarcopenic group. (C) 2-year OS for patients in the SML group versus the non-SML group who developed SML during treatment. (D) 2-year PFS of patients in the pre-treatment sarcopenic group versus the non-sarcopenic group. (E) 2-year PFS of patients in the post-treatment sarcopenic group versus the non-sarcopenic group. (F) 2-year PFS for patients in the SML group versus the non-SML group who developed SML during treatment. SML, significant muscle loss.